No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Cosmos Health 2024 Rev $54.4M
Press Release: Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
Cosmos Health | 10-K: FY2024 Annual Report
Cosmos Health Secures 5-Yr Contract Manufacturing Agreement With Pharmex for 1.5M Units of Antiseptic Drug AMBITASOL 1L
Cosmos Health Launches Sky Premium Life in Albania Through Partnership With Pharma Cell; Secures Initial $300,000 Order
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup